share_log

OPKO Health, Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost Purchases 50,000 Shares

OPKO Health, Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost Purchases 50,000 Shares

奧普科健康公司(納斯達克代碼：OPK)首席執行官菲利普·馬德等·弗羅斯特購買了50,000股
Defense World ·  2022/09/28 06:41

OPKO Health, Inc. (NASDAQ:OPK – Get Rating) CEO Phillip Md Et Al Frost acquired 50,000 shares of the stock in a transaction on Monday, September 26th. The stock was bought at an average price of $1.80 per share, with a total value of $90,000.00. Following the transaction, the chief executive officer now directly owns 197,756,694 shares in the company, valued at approximately $355,962,049.20. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

奧普科健康公司(納斯達克代碼：OPK-GET Rating)首席執行官菲利普·馬德等·弗羅斯特在9月26日(星期一)的一筆交易中收購了50,000股該股。這隻股票是以每股1.80美元的平均價格購買的，總價值為90,000.00美元。交易完成後，首席執行官現在直接擁有該公司197,756,694股，價值約355,962,049.20美元。此次收購是在提交給美國證券交易委員會的一份法律文件中披露的，該文件可以通過此超鏈接.

Phillip Md Et Al Frost also recently made the following trade(s):

菲利普·馬德和阿爾·弗羅斯特最近還進行了以下交易：

Get
到達
OPKO Health
Opko Health
alerts:
警報：
  • On Friday, September 23rd, Phillip Md Et Al Frost purchased 50,000 shares of OPKO Health stock. The shares were acquired at an average price of $1.85 per share, with a total value of $92,500.00.
  • On Wednesday, September 21st, Phillip Md Et Al Frost purchased 50,000 shares of OPKO Health stock. The shares were acquired at an average price of $1.91 per share, with a total value of $95,500.00.
  • On Monday, September 19th, Phillip Md Et Al Frost purchased 50,000 shares of OPKO Health stock. The shares were acquired at an average price of $1.97 per share, with a total value of $98,500.00.
  • On Thursday, September 15th, Phillip Md Et Al Frost purchased 200,000 shares of OPKO Health stock. The shares were acquired at an average price of $2.06 per share, with a total value of $412,000.00.
  • On Wednesday, August 17th, Phillip Md Et Al Frost purchased 200,000 shares of OPKO Health stock. The shares were acquired at an average price of $2.54 per share, with a total value of $508,000.00.
  • On Friday, August 5th, Phillip Md Et Al Frost acquired 350,000 shares of OPKO Health stock. The shares were purchased at an average price of $2.29 per share, with a total value of $801,500.00.
  • 9月23日，星期五，Phillip Md et Al Frost購買了50,000股OPKO Health股票。這些股票是以每股1.85美元的平均價格收購的，總價值為92,500.00美元。
  • 9月21日，星期三，Phillip Md et Al Frost購買了50,000股OPKO Health股票。這些股票是以每股1.91美元的平均價格收購的，總價值為95,500.00美元。
  • 9月19日，星期一，Phillip Md et Al Frost購買了50,000股OPKO Health股票。這些股票是以每股1.97美元的平均價格收購的，總價值為98,500.00美元。
  • 9月15日星期四，Phillip Md et Al Frost購買了20萬股OPKO Health股票。這些股票是以每股2.06美元的平均價格收購的，總價值為412,000.00美元。
  • 8月17日，星期三，Phillip Md et Al Frost購買了20萬股OPKO Health股票。這些股票是以每股2.54美元的平均價格收購的，總價值為508,000.00美元。
  • 8月5日，星期五，Phillip Md et Al Frost收購了OPKO Health的350,000股股票。這些股票是以每股2.29美元的平均價格購買的，總價值為801,500.00美元。

OPKO Health Stock Performance

Opko Health股票表現

Shares of OPK opened at $1.86 on Wednesday. The company has a debt-to-equity ratio of 0.12, a quick ratio of 1.91 and a current ratio of 2.30. OPKO Health, Inc. has a twelve month low of $1.78 and a twelve month high of $5.25. The firm's 50 day moving average price is $2.30 and its two-hundred day moving average price is $2.75. The firm has a market cap of $1.44 billion, a P/E ratio of -6.41 and a beta of 1.75.

週三，OPK的股價開盤報1.86美元。該公司的負債權益比率為0.12，速動比率為1.91，流動比率為2.30。Opko Health，Inc.的12個月低點為1.78美元，12個月高位為5.25美元。該公司的50日移動均線價格為2.30美元，200日移動均線價格為2.75美元。該公司的市值為14.4億美元，市盈率為-6.41，貝塔係數為1.75。

OPKO Health (NASDAQ:OPK – Get Rating) last announced its quarterly earnings results on Thursday, August 4th. The biotechnology company reported ($0.04) earnings per share for the quarter, missing analysts' consensus estimates of ($0.02) by ($0.02). OPKO Health had a negative net margin of 14.18% and a negative return on equity of 7.72%. The company had revenue of $309.90 million during the quarter, compared to the consensus estimate of $326.87 million. During the same period in the previous year, the firm posted ($0.03) EPS. The business's quarterly revenue was down 30.0% compared to the same quarter last year. On average, analysts forecast that OPKO Health, Inc. will post -0.38 EPS for the current fiscal year.
奧普科健康(納斯達克代碼：OPK-GET Rating)上一次公佈季度收益是在8月4日(星期四)。這家生物技術公司公佈的季度每股收益為0.04美元，低於分析師普遍預期的0.02美元和0.02美元。Opko Health的淨利潤率為負14.18%，股本回報率為負7.72%。該公司本季度營收為3.099億美元，而市場普遍預期為3.2687億美元。去年同期，該公司公佈的每股收益為0.03美元。與去年同期相比，該業務的季度收入下降了30.0%。分析師平均預測，OPKO Health，Inc.本財年每股收益將為0.38美元。

Analyst Ratings Changes

分析師評級發生變化

Separately, Piper Sandler decreased their price objective on shares of OPKO Health from $5.00 to $4.00 and set an "overweight" rating for the company in a report on Friday, August 5th.

另外，派珀·桑德勒將OPKO Health的股票目標價從5.00美元下調至4.00美元，並在8月5日星期五的一份報告中為該公司設定了“增持”評級。

Institutional Trading of OPKO Health

OPKO Health的制度性交易

Institutional investors have recently made changes to their positions in the business. Cornerstone Advisory LLC bought a new stake in shares of OPKO Health in the fourth quarter worth $29,000. Humankind Investments LLC bought a new stake in shares of OPKO Health in the first quarter worth $37,000. Guggenheim Capital LLC bought a new stake in shares of OPKO Health in the first quarter worth $38,000. Point72 Hong Kong Ltd bought a new stake in shares of OPKO Health in the first quarter worth $39,000. Finally, Aigen Investment Management LP bought a new stake in shares of OPKO Health in the second quarter worth $29,000. Institutional investors own 27.83% of the company's stock.

機構投資者最近對他們在該業務中的頭寸進行了調整。基石諮詢有限責任公司在第四季度購買了OPKO Health價值2.9萬美元的新股。人類投資有限責任公司在第一季度購買了OPKO Health價值3.7萬美元的新股份。古根海姆資本有限責任公司在第一季度購買了OPKO Health價值3.8萬美元的新股份。Point72 Hong Kong Ltd在第一季度購買了OPKO Health價值3.9萬美元的新股。最後，Aigen Investment Management LP在第二季度購買了OPKO Health價值2.9萬美元的新股。機構投資者持有該公司27.83%的股份。

About OPKO Health

關於OPKO健康

(Get Rating)

(獲取評級)

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers and governmental units; and a novel diagnostic instrument system to provide blood test results in the point-of-care setting, as well as 4Kscore prostate cancer testing services.

Opko Health，Inc.是一家醫療保健公司，在美國、愛爾蘭、智利、西班牙、以色列、墨西哥和國際上從事診斷和製藥業務。該公司的診斷部門經營着BioReference實驗室，該實驗室為疾病的檢測、診斷、評估、監測和治療提供實驗室測試服務，包括深奧測試、分子診斷、解剖病理學、遺傳學、婦女健康以及為醫生辦公室、診所、醫院、僱主和政府單位提供的矯正保健；以及在護理地點提供血液測試結果的新型診斷儀器系統，以及4KScore前列腺癌測試服務。

Featured Articles

專題文章

  • Get a free copy of the StockNews.com research report on OPKO Health (OPK)
  • Defensive Stocks For A Volatile Market
  • Will UPS Be Next to Deliver a Warning?
  • SunPower Is Ready To Power Up Triple-Digit Earnings Gains
  • Is This the Darkest Before the Dawn for Gap Stock?
  • Build A Better Tech Portfolio With Jabil Inc.
  • 免費獲取StockNews.com關於OPKO健康的研究報告(OPK)
  • 防禦性股票應對動盪的市場
  • UPS會成為下一個發出警告的公司嗎？
  • SunPower準備推動三位數的收益增長
  • 這是Gap Stock黎明前最黑暗的一次嗎？
  • 與捷普公司一起打造更好的技術產品組合。

Receive News & Ratings for OPKO Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OPKO Health and related companies with MarketBeat.com's FREE daily email newsletter.

接受OPKO健康日報的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對OPKO Health和相關公司的最新新聞和分析師評級的每日簡要摘要。

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論